Regulation - daclatasvir

Filter

Current filters:

daclatasvir

Popular Filters

Bristol-Myers Squibb files for US approval of daclatasvir and asunaprevir for hepatitis C

Bristol-Myers Squibb files for US approval of daclatasvir and asunaprevir for hepatitis C

07-04-2014

US pharma major Bristol-Myers Squibb has submitted New Drug Applications with the US Food and Drug Administration…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirNorth AmericaPharmaceuticalRegulationUSA

FDA Breakthrough designation for all-oral daclatasvir for chronic hepatitis C

24-02-2014

The US Food and Drug Administration has granted drug major Bristol-Myers Squibb’s investigational DCV…

Anti-viralsBristol-Myers SquibbdaclatasvirNorth AmericaPharmaceuticalRegulationUSA

Bristol-Myers files for Japanese approval of first all-oral, interferon/ribavirin-free hep C treatment

Bristol-Myers files for Japanese approval of first all-oral, interferon/ribavirin-free hep C treatment

03-11-2013

US drug major Bristol-Myers Squibb has filed a New Drug Application with Japan’s Pharmaceutical and…

Anti-viralsAsia-PacificasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalRegulation

Back to top